Starbucks to drop GLP-1 coverage for weight loss as employers trim benefits

Starbucks will end coverage of GLP-1 drugs prescribed for weight loss beginning in October 2026 ^[2]. The coffee chain's decision puts it alongside other big employers that have trimmed obesity treatment from their health plans as medical spending rises ^[1][2].

Weight-loss medications are now the largest single factor behind a record jump in the cost of employer-sponsored health insurance expected next year, according to The Washington Post ^[1]. Marsh's yearly survey of employer health plans projects that total health benefit cost per employee will climb 8.2% on average in 2027, the biggest increase since 2003 — and that projection already accounts for steps companies are taking to hold costs down ^[2]. Forecasts from Aon and Business Group on Health likewise pointed to high single-digit growth ^[2]. Part of the increase is expected to reach workers through changes to plan design or a larger share of premiums ^[2].

Employers narrow who qualifies

Employer coverage of GLP-1s for obesity has been sliding: 72% of companies offered it in 2025, compared with 60% in 2026, per Business Group on Health ^[1][2]. That survey found about two-thirds of companies still cover weight-loss drugs, while 10% intend to drop the coverage in 2027 ^[1].

Sara Drake, a pharmaceutical benefits specialist at Marsh, said 6% of employers dropped GLP-1 coverage during 2026 and 5% plan to do so next year. A larger share — 27% — is adding conditions instead, such as a minimum body-mass index or a documented diagnosis of sleep apnea or a cardiac condition ^[1]. Drake said employers want to keep offering the benefit, but "they're really feeling constrained" ^[1].

PepsiCo stopped covering weight-loss medications for anyone but employees with diabetes, telling workers that "prescription weight loss medications have become one of the fastest-growing costs in the PepsiCo Plans" ^[1]. Cigna ended the coverage this summer for its own employees ^[1]. Bank of America's CEO has said the company pays $250 million a year for workers' GLP-1s ^[1].

Other benefits are being scaled back too. Disney is dropping health coverage for working spouses who have access to their own plans next year, and Deloitte is reducing parental leave and IVF funding for certain employees ^[2]. Dan Mendelson, CEO of Morgan Health, JPMorgan Chase's employer health division, said, "Employers don't wake up in the morning and say, 'I want to cut benefits.' It's kind of a last resort" ^[2].

Why it matters for patients

In the United States, employers generally decide which drugs their plans cover, said Matthew Rae of the KFF policy organization ^[1]. Most still cover GLP-1s for Type 2 diabetes, because poorly managed diabetes is expensive to treat, but a growing number cover them only for that ^[1]. Elliot Rosenblum of Symphony Consulting noted that employers that buy fully insured plans may have no say at all: an insurer can decline to offer GLP-1 coverage if the math doesn't work ^[1].

Employees often cannot see the covered-drug list before they enroll, because most companies don't publish it ^[1]. Ashley Defay, an HR worker in Chicago, learned only after changing jobs that her new employer excluded the drug. She appealed several times, citing her prediabetes and sleep apnea, and was denied. She stopped the medication, regained the weight, spent about $200 a month on a compounded version that she said didn't help, and now pays $450 a month for brand-name Zepbound — more than a third of the $15,000 raise her job change brought ^[1].

Prices have fallen through direct-to-consumer options, but losing coverage can still mean hundreds of dollars a month ^[1]. Restrictions tied to BMI or specific diagnoses mean eligibility can hinge on meeting criteria ^[1].

It has not been reported how many employees will lose coverage in total, or which Starbucks workers and plan types the change covers.

What happens next

Starbucks' change takes effect in October 2026 ^[2]. During 2027 plan-year decisions, 5% of employers told Marsh they plan to drop GLP-1 coverage and 27% are adding restrictions ^[1]; 10% told Business Group on Health they plan to drop obesity coverage ^[1]. Marsh projects an 8.2% average increase in health benefit cost per employee ^[1][2].

Caroline Susie, a Marsh dietitian who advises companies on benefits, said none of her clients question whether the drugs work, describing the tradeoff as "balancing empathy with economics" and noting "in the short term, there just is not a return on investment" ^[1].